文献速递生殖医学

实施非侵入性植入前非整倍体遗传学检测(niPGT-A)胚胎培养方案对胚胎存活力和临床结局的影响

The impact of implementing a non-invasive preimplantation genetic testing for aneuploidies (niPGT-A) embryo culture protocol on embryo viability and clinical outcomes.
PubMed 文献 · Hum Reprod · 2024-01-01

本研究比较实施niPGT-A胚胎培养方案(n=428例,476周期)与标准侵入性PGT-A培养方案(n=1392例)的临床结局。结果显示两组平均年龄、获卵数、受精率及活检囊胚数无显著差异,按活检日分层后临床妊娠率、流产率及持续妊娠率(≥12周)亦无显著差异。作者指出方案调整不影响可移植囊胚数及总体临床结局。

要点

  • niPGT-A培养方案调整不影响囊胚存活力和妊娠结局。
  • 按活检日分层后,临床妊娠率、流产率及持续妊娠率无显著差异。
  • 两组平均年龄、获卵数、受精率及活检囊胚数无显著差异。

核心结论

  • 实施niPGT-A胚胎培养方案对囊胚存活力和妊娠结局无影响
  • 作者指出方案调整不影响可移植囊胚数及移植胚胎的总体临床结局
  • 去除侵入性活检步骤能否进一步改善妊娠率尚待进一步研究

研究设计与样本

  • 作为比较niPGT-A与侵入性PGT-A一致性试验的一部分,六家IVF诊所实施特定niPGT-A胚胎培养方案
  • niPGT-A研究组428例患者(476周期),对照组1392例患者接受标准PGT-A培养方案
  • 研究期间为2018年4月至2020年12月
  • A诊所所有胚胎(97周期、355枚胚胎)培养至第6或7天
  • 其余诊所(B-F,379周期)中231/985枚囊胚(23.5%)于第5天活检,754/985枚(76.5%)遵循niPGT-A方案

主要发现

  • 研究组与对照组平均年龄、获卵数、受精率及活检囊胚数无显著差异
  • 按活检日分层后,研究组与对照组临床妊娠率、流产率及持续妊娠率(≥12周)无显著差异
  • niPGT-A培养方案调整不影响可移植囊胚数及移植胚胎的总体临床结局

局限性

  • 局限性源于研究的回顾性性质
  • 研究在侵入性PGT-A患者中进行,并非专门使用niPGT-A病例

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Are modifications in the embryo culture protocol needed to perform non-invasive preimplantation genetic testing for aneuploidies (niPGT-A) affecting clinical reproductive outcomes, including blastocyst development and pregnancy outcomes? SUMMARY ANSWER: The implementation of an embryo culture protocol to accommodate niPGT-A has no impact on blastocyst viability or pregnancy outcomes. WHAT IS KNOWN ALREADY: The recent identification of embryo cell-free (cf) DNA in spent blastocyst media has created the possibility of simplifying PGT-A. Concerns, however, have arisen at two levels. First, the representativeness of that cfDNA to the real ploidy status of the embryo. Second, the logistical changes that need to be implemented by the IVF laboratory when performing niPGT-A and their effect on reproductive outcomes. Concordance rates of niPGT-A to invasive PGT-A have gradually improved; however, the impact of culture protocol changes is not as well understood. STUDY DESIGN, SIZE, DURATION: As part of a trial examining concordance rates of niPGT-A versus invasive PGT-A, the IVF clinics implemented a specific niPGT-A embryo culture protocol. Briefly, this involved initial culture of fertilized oocytes following each laboratory standard routine up to Day 4. On Day 4, embryos were washed and cultured individually in 10 μl of fresh media. On Day 6 or 7, blastocysts were then biopsied, vitrified, and media collected for the niPGT-A analysis. Six IVF clinics from the previously mentioned trial were enrolled in this analysis. In the concordance trial, Clinic A cultured all embryos (97 cycles and 355 embryos) up to Day 6 or 7, whereas in the remaining clinics (B-F) (379 cycles), nearly a quarter of all the blastocysts (231/985: 23.5%) were biopsied on Day 5, with the remaining blastocysts following the niPGT-A protocol (754/985: 76.5%). During the same period (April 2018-December 2020), the IVF clinics also performed standard invasive PGT-A, which involved culture of embryos up to Days 5, 6, or 7 when blastocysts were biopsied and vitrified. PARTICIPANTS/MATERIALS, SETTING, METHODS: In total, 428 (476 cycles) patients were in the niPGT-A study group. Embryos from 1392 patients underwent the standard PGT-A culture protocol and formed the control group. Clinical information was obtained and analyzed from all the patients. Statistical comparisons were performed between the study and the control groups according to the day of biopsy. MAIN RESULTS AND THE ROLE OF CHANCE: The mean age, number of oocytes, fertilization rates, and number of blastocysts biopsied were not significantly different for the study and the control group. Regarding the overall pregnancy outcomes, no significant effect was observed on clinical pregnancy rate, miscarriage rate, or ongoing pregnancy rate (≥12 weeks) in the study group compared to the control group when stratified by day of biopsy. LIMITATIONS, REASONS FOR CAUTION: The limitations are intrinsic to the retrospective nature of the study, and to the fact that the study was conducted in invasive PGT-A patients and not specifically using niPGT-A cases. WIDER IMPLICATIONS OF THE FINDINGS: This study shows that modifying current IVF laboratory protocols to adopt niPGT-A has no impact on the number of blastocysts available for transfer and overall clinical outcomes of transferred embryos. Whether removal of the invasive biopsy step leads to further improvements in pregnancy rates awaits further studies. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by Igenomix. C.R., L.N.-S., and D.V. are employees of Igenomix. D.S. was on the Scientific Advisory Board of Igenomix during the study. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov (NCT03520933).

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Sakkas D, Navarro-Sánchez L, Ardestani G, et al. The impact of implementing a non-invasive preimplantation genetic testing for aneuploidies (niPGT-A) embryo culture protocol on embryo viability and clinical outcomes. Hum Reprod. 2024. PMID: 39059790. doi:10.1093/humrep/deae156

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。